Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations

A. S. Whittemore, Raymond Balise, P. D P Pharoah, R. A. DiCioccio, I. Oakley-Girvan, S. J. Ramus, M. Daly, M. B. Usinowicz, K. Garlinghouse-Jones, B. A J Ponder, S. Buys, R. Senie, I. Andrulis, E. John, J. L. Hopper, M. S. Piver

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

Women with mutations of the genes BRCA1 or BRCA2 are at increased risk of ovarian cancer. Oral contraceptives protect against ovarian cancer in general, but it is not known whether they protect against the disease in carriers of these mutations. We obtained self-reported lifetime histories of oral contraceptive use from 451 women who carried mutations of BRCA1 or BRCA2. We used conditional logistic regression to estimate the odds ratios associated with oral contraceptive use, comparing the histories of 147 women with ovarian cancer (cases) to those of 304 women without ovarian cancer (controls) who were matched to cases on year of birth, country of residence and gene (BRCA1 vs BRCA2). Reference ages for controls had to exceed the ages at diagnosis of their matched cases. After adjusting for parity, the odds-ratio for ovarian cancer associated with use of oral contraceptives for at least 1 year was 0.85 (95 percent confidence interval, 0.53-1.36). The risk decreased by 5% (1-9%) with each year of use (P for trend = 0.01). Use for 6 or more years was associated with an odds-ratio of 0.62 (0.35-1.09). These data support the hypothesis that long-term oral contraceptive use reduces the risk of ovarian cancer among women who carry mutations of BRCA1 or BRCA2.

Original languageEnglish (US)
Pages (from-to)1911-1915
Number of pages5
JournalBritish Journal of Cancer
Volume91
Issue number11
DOIs
StatePublished - Nov 29 2004
Externally publishedYes

Fingerprint

Oral Contraceptives
Ovarian Neoplasms
Mutation
BRCA1 Gene
Odds Ratio
BRCA2 Gene
Parity
Logistic Models
Parturition
Confidence Intervals

Keywords

  • BRCA1
  • BRCA2
  • Oral contraceptives, ovarian cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Whittemore, A. S., Balise, R., Pharoah, P. D. P., DiCioccio, R. A., Oakley-Girvan, I., Ramus, S. J., ... Piver, M. S. (2004). Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. British Journal of Cancer, 91(11), 1911-1915. https://doi.org/10.1038/sj.bjc.6602239

Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. / Whittemore, A. S.; Balise, Raymond; Pharoah, P. D P; DiCioccio, R. A.; Oakley-Girvan, I.; Ramus, S. J.; Daly, M.; Usinowicz, M. B.; Garlinghouse-Jones, K.; Ponder, B. A J; Buys, S.; Senie, R.; Andrulis, I.; John, E.; Hopper, J. L.; Piver, M. S.

In: British Journal of Cancer, Vol. 91, No. 11, 29.11.2004, p. 1911-1915.

Research output: Contribution to journalArticle

Whittemore, AS, Balise, R, Pharoah, PDP, DiCioccio, RA, Oakley-Girvan, I, Ramus, SJ, Daly, M, Usinowicz, MB, Garlinghouse-Jones, K, Ponder, BAJ, Buys, S, Senie, R, Andrulis, I, John, E, Hopper, JL & Piver, MS 2004, 'Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations', British Journal of Cancer, vol. 91, no. 11, pp. 1911-1915. https://doi.org/10.1038/sj.bjc.6602239
Whittemore AS, Balise R, Pharoah PDP, DiCioccio RA, Oakley-Girvan I, Ramus SJ et al. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. British Journal of Cancer. 2004 Nov 29;91(11):1911-1915. https://doi.org/10.1038/sj.bjc.6602239
Whittemore, A. S. ; Balise, Raymond ; Pharoah, P. D P ; DiCioccio, R. A. ; Oakley-Girvan, I. ; Ramus, S. J. ; Daly, M. ; Usinowicz, M. B. ; Garlinghouse-Jones, K. ; Ponder, B. A J ; Buys, S. ; Senie, R. ; Andrulis, I. ; John, E. ; Hopper, J. L. ; Piver, M. S. / Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. In: British Journal of Cancer. 2004 ; Vol. 91, No. 11. pp. 1911-1915.
@article{d4c5577616a14d008ee1e1ef85f90931,
title = "Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations",
abstract = "Women with mutations of the genes BRCA1 or BRCA2 are at increased risk of ovarian cancer. Oral contraceptives protect against ovarian cancer in general, but it is not known whether they protect against the disease in carriers of these mutations. We obtained self-reported lifetime histories of oral contraceptive use from 451 women who carried mutations of BRCA1 or BRCA2. We used conditional logistic regression to estimate the odds ratios associated with oral contraceptive use, comparing the histories of 147 women with ovarian cancer (cases) to those of 304 women without ovarian cancer (controls) who were matched to cases on year of birth, country of residence and gene (BRCA1 vs BRCA2). Reference ages for controls had to exceed the ages at diagnosis of their matched cases. After adjusting for parity, the odds-ratio for ovarian cancer associated with use of oral contraceptives for at least 1 year was 0.85 (95 percent confidence interval, 0.53-1.36). The risk decreased by 5{\%} (1-9{\%}) with each year of use (P for trend = 0.01). Use for 6 or more years was associated with an odds-ratio of 0.62 (0.35-1.09). These data support the hypothesis that long-term oral contraceptive use reduces the risk of ovarian cancer among women who carry mutations of BRCA1 or BRCA2.",
keywords = "BRCA1, BRCA2, Oral contraceptives, ovarian cancer",
author = "Whittemore, {A. S.} and Raymond Balise and Pharoah, {P. D P} and DiCioccio, {R. A.} and I. Oakley-Girvan and Ramus, {S. J.} and M. Daly and Usinowicz, {M. B.} and K. Garlinghouse-Jones and Ponder, {B. A J} and S. Buys and R. Senie and I. Andrulis and E. John and Hopper, {J. L.} and Piver, {M. S.}",
year = "2004",
month = "11",
day = "29",
doi = "10.1038/sj.bjc.6602239",
language = "English (US)",
volume = "91",
pages = "1911--1915",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations

AU - Whittemore, A. S.

AU - Balise, Raymond

AU - Pharoah, P. D P

AU - DiCioccio, R. A.

AU - Oakley-Girvan, I.

AU - Ramus, S. J.

AU - Daly, M.

AU - Usinowicz, M. B.

AU - Garlinghouse-Jones, K.

AU - Ponder, B. A J

AU - Buys, S.

AU - Senie, R.

AU - Andrulis, I.

AU - John, E.

AU - Hopper, J. L.

AU - Piver, M. S.

PY - 2004/11/29

Y1 - 2004/11/29

N2 - Women with mutations of the genes BRCA1 or BRCA2 are at increased risk of ovarian cancer. Oral contraceptives protect against ovarian cancer in general, but it is not known whether they protect against the disease in carriers of these mutations. We obtained self-reported lifetime histories of oral contraceptive use from 451 women who carried mutations of BRCA1 or BRCA2. We used conditional logistic regression to estimate the odds ratios associated with oral contraceptive use, comparing the histories of 147 women with ovarian cancer (cases) to those of 304 women without ovarian cancer (controls) who were matched to cases on year of birth, country of residence and gene (BRCA1 vs BRCA2). Reference ages for controls had to exceed the ages at diagnosis of their matched cases. After adjusting for parity, the odds-ratio for ovarian cancer associated with use of oral contraceptives for at least 1 year was 0.85 (95 percent confidence interval, 0.53-1.36). The risk decreased by 5% (1-9%) with each year of use (P for trend = 0.01). Use for 6 or more years was associated with an odds-ratio of 0.62 (0.35-1.09). These data support the hypothesis that long-term oral contraceptive use reduces the risk of ovarian cancer among women who carry mutations of BRCA1 or BRCA2.

AB - Women with mutations of the genes BRCA1 or BRCA2 are at increased risk of ovarian cancer. Oral contraceptives protect against ovarian cancer in general, but it is not known whether they protect against the disease in carriers of these mutations. We obtained self-reported lifetime histories of oral contraceptive use from 451 women who carried mutations of BRCA1 or BRCA2. We used conditional logistic regression to estimate the odds ratios associated with oral contraceptive use, comparing the histories of 147 women with ovarian cancer (cases) to those of 304 women without ovarian cancer (controls) who were matched to cases on year of birth, country of residence and gene (BRCA1 vs BRCA2). Reference ages for controls had to exceed the ages at diagnosis of their matched cases. After adjusting for parity, the odds-ratio for ovarian cancer associated with use of oral contraceptives for at least 1 year was 0.85 (95 percent confidence interval, 0.53-1.36). The risk decreased by 5% (1-9%) with each year of use (P for trend = 0.01). Use for 6 or more years was associated with an odds-ratio of 0.62 (0.35-1.09). These data support the hypothesis that long-term oral contraceptive use reduces the risk of ovarian cancer among women who carry mutations of BRCA1 or BRCA2.

KW - BRCA1

KW - BRCA2

KW - Oral contraceptives, ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=19944426928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944426928&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6602239

DO - 10.1038/sj.bjc.6602239

M3 - Article

C2 - 15545966

AN - SCOPUS:19944426928

VL - 91

SP - 1911

EP - 1915

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 11

ER -